Selexipag
Overview
Selexipag is an oral selective IP prostacyclin receptor agonist used in the treatment of pulmonary arterial hypertension (PAH). It acts by relaxing the muscles in the walls of blood vessels to reduce the elevated pulmonary blood pressure to normal levels.
API suppliers (7)
Suppliers of Selexipag evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 5 of 7 suppliers.
3 of 7 hold a GMP certificate on record in the EU or UK registers
- Apotex Pharmachem India Pvt. Ltd.India1 active DMF
- Alembic Pharmaceuticals LimitedIndia1 active DMF GMP on record
- Zhejiang Huayi Pharmaceutical Co., Ltd.China1 active DMF
- MSN Laboratories Private LimitedIndia1 active DMF GMP on record
- HONOUR LAB LTDIndia1 active DMF GMP on record
- SABA ILAC SANAYII VE TICARET ANONIM SIRKETI1 active DMF
- BIOPHORE INDIA PHARMACEUTICALS PVT LTD1 active DMF
Patent & exclusivity (US)
Per the FDA Orange Book (25 approved US products), the latest listed US patent on Selexipag expires 1 Jun 2037 and exclusivity 23 Nov 2029. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Selexipag? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.